BioSyent Pharma Inc. Launches Feramax'TM': A Unique Oral Hematinic

Published: Sep 25, 2006

MISSISSAUGA, ONTARIO -- (MARKET WIRE) -- September 25, 2006 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) subsidiary BioSyent Pharma Inc. is pleased to announce that it is launching FeraMAX™, an oral hematinic, to the Canadian healthcare market via pharmaceutical wholesalers and retail pharmacies. FeraMAX™ helps the body form red blood cells and is indicated for the prevention and treatment of iron deficiency anemia (IDA). It is formulated with polysaccharide-iron complex (PIC), which provides a non-ionic delivery system that allows the iron ion to be delivered to the bloodstream without coming in to contact with the stomach or upper gastro-intestinal tract. This non-ionic formulation leads to improved iron absorption by the body and eliminates adverse side effects such as nausea, constipation, diarrhea, and epigastric pain associated with many other iron formulations.

Back to news